Article – “DEA quietly classifies CBD oil as schedule 1 drug
DEA QUIETLY CLASSIFIES CBD OIL AS SCHEDULE 1 DRUG
On Wednesday, the DEA took yet another swipe at marijuana by amending its already bizarre classification of pot as a Schedule I drug. Now, all extracts, including cannabidiol (CBD), will be listed right up there with heroin as a “drug with no medical use.”
Tell that to the thousands of epilepsy sufferers, who are mercifully enjoying relief from intractable epilepsy and polymorphic seizures.
Under their new drug code, entitled “Establishment of a New Drug Code for Marihuana Extract,” the DEA announced it was “creating a separate code number for marihuana extract with the following definition: ‘Meaning an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant.’ Extracts of marihuana will continue to be treated as Schedule I controlled substances.”
The DEA is essentially giving itself license to better track which scientists are studying marijuana and which ones are researching CBD and other extracts. At the moment, when researchers apply to the DEA for permission to study weed, there’s no way for them to specify whether they intend to only work on extracts.
“It’s an internal accounting mechanism for us,” DEA spokesperson Russell Baer told VICE News. “The purpose is to drill down and get more accurate information about research that’s being conducted with CBD in particular.”
Yeah, right.
In addition to the fact that this move is likely illegal, it is clearly backward and could obstruct medical research efforts that have already produced effective CBD-derived medications. One such medication is Epidiolex, developed by GW Pharmaceuticals for the treatment of Dravet’s Syndrome, which recently came one step closer to FDA approval.
“This action is beyond the DEA’s authority,” Robert Hoban, a Colorado cannabis attorney and adjunct professor of law at the University of Denver, told the International Business Times. “The DEA can only carry out the law, they cannot create it. Here, they’re purporting to create an entirely new category called ‘marijuana extracts,’ and by doing so wrest control over all cannabinoids. They want to call all cannabinoids illegal. But they don’t have the authority to do that.”
The idea of classifying weed and now CBD, as well as cannabis extracts (psychoactive or not), as a Schedule 1 drug, along with heroin is nothing less than an outrage.
Original Article found at : http://hightimes.com/news/dea-quietly-classifies-cbd-oil-as-schedule-1-drug/
CBG – The Next Big Cannabinoid Strain by Herb.com
Enhancements in medical marijuana research have increased substantially since the legalization of marijuana. With states like Colorado receiving $10 million in research funding, we will continue to see an increase in the knowledge and benefits of marijuana. As restrictions on cannabis testing continue to decrease, we will finally see the true reasoning behind the Government and pharmaceutical bond.
Medical marijuana patients are currently able to purchase various strains with high-THC and high-CBD levels. CBG marijuana strains are practically unavailable on the market right now, but this won’t be true for long.
Cannabinoids all start off as CBG
Cannabigerol (CBG) is a minor cannabinoid found during the early stages of the marijuana growing cycle and extracted from budding plants during their flowering stage. This makes it difficult to obtain in large quantities. Industrial hemp was recently discovered as a producer of higher levels of CBG than most cannabis strains. After further research proved the reasoning of this to be because of a recessive gene, breeders took note. Using this information, the breeders were able to create strains with a recessive gene that increases the CBG levels.
In January 2015, researchers studying CBG in mice discovered neuroprotective effects with Huntington’s disease and have shown promising results in slowing down colon cancer. CBG marijuana strains will hopefully be used therapeutically as an antidepressant, and as a functioning painkiller. Researchers suggest that CBG marijuana strains will also be beneficial for the treatment of psoriasis, glaucoma, multiple sclerosis and skin diseases.
How CBG is effective
CBG is effective in a range of treatment and therapies, according to a report by Ethan B Russo, published in the British Journal of Pharmacology. These include:
- Producing modest antifungal effects
- Inhibiting keratinocyte proliferation — may be useful in treatment of psoriasis
- In conjunction with l-limonene (citrus terpene found in cannabis), CBG shows promising results to fight breast cancer
- Pure CBG and CBD cannabinoids can powerfully inhibit MRSA
Medical marijuana patients are seeing the benefits from legalization in certain states with the boost in medical marijuana availability. The business is booming, and different strains with different benefits are being introduced rapidly to the market.
Teams of chemists in California and Oregon have developed lab testing, which is becoming an industry trend. Lab testing allows patients to be matched with a strain based on the cannabinoids profile. A Cannabinoid profile allows the patient to see the breakdown of cannabinoids in their medicine to an exact percentage. This has lead to an increase of interest in minor cannabinoids from patients, like CBD and CBG marijuana strains.
CBG coming soon
You won’t find many CBG marijuana strains currently on the market, but thanks to breeders like those at TGA genetics Subcool Seeds, the breed Mikey Kush exists. Mikey Kush strain is a Sativa-dominant strain testing with high levels of CBG and THC levels of 28.6%. CBG marijuana strains are becoming more available in Europe, and will most likely start to be seen on the shelves in North American soon. Research will surely continue, and as public interest increases, growers will be encouraged to produce high-CBG strains themselves.
With the advancement in CBG marijuana strains, it will permit growers to create CBD-CBG hybrid strains. This will introduce a whole new possibility into the future of marijuana strains. The future of medical marijuana seems positive, and both researchers and growers sound particularly optimistic about the CBG marijuana strain.
According to an article on CDXLife:
Whether incorporated in your therapy via medical marijuana or used in oil, CBG offers huge benefit to a patient who is fighting a wide range of illnesses.
Original Article found at : http://herb.co/2015/10/08/cbg-the-next-big-cannabinoid-strain/
The Endocannbiniod System and response..We Are All One!
The Endocannabinoid System- An Overview
The following information is presented for educational purposes only. BounceBack Botanical offers this information to provide an understanding of the potential applications of cannabinoids. Links to third party websites do not constitute an endorsement of these organizations by BounceBack Botanicals and none should be inferred.
The endocannabinoid system is responsible for regulating balance in our body’s immune response, communication between cells, appetite and metabolism, memory, and more. In spite of the integral role this system takes on, until recently it remained an unknown part of the human body’s functions. Named for the plant that inspired its discovery, the endocannabinoid system’s importance is only just becoming understood by the medical community. It is through this system that the naturally occurring cannabinoids from medical marijuana interact with our bodies and trigger its beneficial effects. With the potential to greatly affect the way our bodies work, it is essential that we recognize how to maintain a healthy endocannabinoid system.
The History of the Endocannabinoid System
Across cultures and building through the 19th century, extractions of the cannabis plant were widely used for a number of medicinal purposes. However, following practical prohibition of the cannabis plant in 1937 by the federal government for fear of abuse of its psychoactive properties, medical use and, subsequently, experimentation and study of cannabis were eliminated, stalling the progress of our understanding of the endocannabinoid system and the possible medical effects of cannabis. For nearly 50 years, marijuana fell from popular pharmacopeia and was labelled as illicit in the minds of Americans.
Then the endocannabinoid system was defined in the early 1990’s when Lisa Matsuda announced that her team at the National Institute of Mental Health had first identified a THC-sensitive receptor in lab rat brains. Following this revelation, the National Academy of Science predicted the 1990’s would be the “Decade of the Brain”. It turned out to be true as the following 10 year period would produce “more advances in neuroscience than in all previous years combined” (Lee, 2012).
Since then, scientists have labored to learn as much as they can about the endocannabinoid system, our naturally occurring cannabinoids, and the ways cannabis alters this balance, publishing over 20,000 scientific studies referencing cannabinoids in just the last two decades.
What Is the Endocannabinoid System?
The endocannabinoid system is made up of several integrated mechanisms: enzymes responsible for creating and destroying cannabinoids, receptor sites on cells to receive cannabinoids, and the endocannabinoids themselves (cannabinoid-like compounds that are naturally produced by the human body). These mechanisms are predominantly responsible for communication within the body to best regulate various biological responses.
One of the prime questions being raised in these early studies was whether the body produces its own natural equivalents to the previously discovered compounds called phytocannabinoids, like THC and CBD, found in the cannabis plant (Mandal, 2014). The answer turned out to be yes in the form of endocannabinoids, like the two prominent analogs to THC and CBD, anandamide and 2-AG (Pacher et al, 2006). With the understanding that humans create our own cannabinoids, the door to deconstructing their purpose was opened.
Endocannabinoids are created then in response to needs within the larger physiological system and are largely understood to be used for the body’s regulatory functions. Acting backwards on presynaptic cells, they control the volume at which communicating signals are sent. It is in this way that endocannabinoids affect duration and intensity of the wide range of physiological processes under their control.
However, it has been repeatedly noted that, while the endocannabinoid system is linked to a number of important processes and is concentrated in the brain, nervous system, and reproductive organs, it does not affect regions of the brain controlling heart and lung function. This is one of the main reasons that fatal overdoses of cannabinoids do not occur (NCI, 2016).
When the body creates neurotransmitters for the endocannabinoid system, they are picked up by specialized cannabinoid receptors. These receptors are found in a wide range of physiological regions, such as in the immune system, a number of organs, glands, connective tissue, and most significantly, in the brain. Endocannabinoids interact with these receptors with the goal of helping the body achieve homeostasis, or equilibrium within the body despite outside influences (Alger, 2013).
The endocannabinoid system’s receptor sites include CB1 and CB2 receptor variants, which respond differently to different cannabinoids (Pacher et al, 2006). CB1 receptors are most prevalent in the central nervous system and are linked to modulating stress and anxiety, increased appetite and decreased nausea, immune system balance, and even inhibition of tumors. CB2 receptors are found mostly on cells in the immune system and seem to dominate in fighting inflammation and damage to tissue. Some cells can even contain both types of receptors, each responsible for a different function.
How Does the Endocannabinoid System Affect Health?
Since discovering the endocannabinoid system and its parts, researchers have worked to further understand how the endocannabinoid system may be used therapeutically to decrease pain , prevents neurodegenerative diseases and promote general health. Overall, research indicates that the endocannabinoid system helps ensure that the body’s immune and central nervous systems are running correctly. Finding ways to modulate the endocannabinoid system’s activity opens pathways to an amazingly disparate set of chronic diseases and disorders (Pacher and Kunos, 2013). This list includes difficult conditions likeParkinson’s, Multiple Sclerosis and even cancer.
Memory
There is also evidence that the endocannabinoid system may aid in the deletion of old memories (Ruehle et al, 2012). The extinction of aversive memories is important to the progress of PTSD patients and in behavior conditioning for those with chronic anxiety. By allowing patients to forget painful memories, they can reset their stress and anxiety responses to certain experiences and substitute a more positive reaction.
Appetite & Weight
Cannabis is well known for its ability to increase the appetite. However, because endocannabinoids are used internally for appetite control, inverse agonists to the CB1 receptor can be used to combat obesity by shutting off the body’s desire for food (Pagotto et al, 2005). The opposite can be accomplished by stimulating appetite in those suffering from wasting syndrome and allowing them to gain weight (Kogan and Mechoulam, 2007). Finally, endocannabinoids also regulate metabolism and help control the transfer of energy through cells, ensuring optimal use of the food we do take in.
Anxiety
In today’s world, it is a common reality that the natural cycle of anxiety and physical response cannot be shut off due to constant exposure to stressors. Because cannabinoids affect the body’s glandular response to continued stress to regulate and temper response, the endocannabinoid system has implications for the way modern humans process long term stress and other enduring anxiety triggers (Akirav).
Immune Function & Inflammation
Additionally, endocannabinoids promote proper immune function to allow for a greater overall wellness. The role they play in immune homeostasis prevents “spontaneous activation of immune cell function”, helping to prevent inflammation and possibly even resulting neurological diseases (Pandey et al, 2009).
As we continue to learn more about the endocannabinoid system, we will also learn about the potential for the scope of active compounds from cannabis (like THC, CBD, and CBN) to be used therapeutically.
Should I Add Cannabinoids to My Body?
One theory about how the endocannabinoid system relates to our overall health is the proposed endocannabinoid deficiency syndrome, or CECD, which speculates that for some people, the body does not generate enough endocannabinoids (Smith and Wagner, 2014). This concept further speculates that the deficiency could be the root cause of many autoimmune disorders, including migraines, fibromyalgia, and IBS.
One of the main obstacles to the acceptance and use of cannabis and its active cannabinoids in medicine is the problem of abuse for its psychoactivity. However, this issue does not arise in a number of possible approaches to the manipulation of the endocannabinoid system: such as when an antagonist to the CB1 receptor is applied, when the production or transportation of endocannabinoids is altered, or when a non-psychoactive agonist to the CB2 receptor, like CBD, is used for therapeutic results (Pacher and Kunos, 2013).
Phytocannabinoids, like the THC from cannabis or the concentrated CBD in hemp, obviously affect the endocannabinoid system. However, it has also been shown that non-psychoactive phytocannabinoids from other plants, and even other compounds like terpenes and flavonoids, are picked up by receptors in our endocannabinoid systems (Gertsch et al, 2010). Because small doses of phytocannabinoids can encourage the body to create more naturally occurring endocannabinoids and their receptors, it may be possible to bolster the sensitivity of our native systems with regular cannabinoid supplements (Pacher et al, 2006).
Overall, significant research must still be done to better understand the impact of the endocannabinoid system on our overall health and how supplementing our natural endocannabinoid production with plant-based cannabinoids may play a significant therapeutic role in our health. However, extensive early studies show great potential for using this vital system to the benefit of patient health.
by Medical Marijuana Inc.
References:
Akirav, I. (n.d.) Role of the endocannabinoid system in anxiety and stress-related disorders. Intech Open. Retrieved from http://cdn.intechopen.com/pdfs/17314/InTech-Role_of_the_endocannabinoid_system_in_anxiety_and_stress_related_disorders.pdf
Alger, B. E. (2013). Getting High on the Endocannabinoid System. Cerebrum: The Dana Forum on Brain Science, 2013, 14. Gertsch, J., Pertwee, R. G., & Di Marzo, V. (2010). Phytocannabinoids beyond the Cannabis plant – do they exist? British Journal of Pharmacology, 160(3), 523–529. http://doi.org/10.1111/j.1476-5381.2010.00745.x
Kogan, N. M., & Mechoulam, R. (2007). Cannabinoids in health and disease. Dialogues in Clinical Neuroscience, 9(4), 413–430.
Lee, M. (2012). The Discovery of the endocannabinoid system. Retrieved from http://www.beyondthc.com/wp-content/uploads/2012/07/eCBSystemLee.pdf
Mandal, A. (2014, June 14). Phytocannabinoids. News Medical. Retrieved from http://www.news-medical.net/health/Phytocannabinoids.aspx
National Cancer Institute. (2016). Cannabis and cannabinoids. Retrieved from http://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq#section/_11
PACHER, P., BÁTKAI, S., & KUNOS, G. (2006). The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacological Reviews, 58(3), 389–462. http://doi.org/10.1124/pr.58.3.2
Pacher, P., & Kunos, G. (2013). Modulating the endocannabinoid system in human health and disease: successes and failures. The FEBS Journal, 280(9), 1918–1943. http://doi.org/10.1111/febs.12260
Pagotto, U., Vicennati, V., & Pasquali, R. (2005). The endocannabinoid system and the treatment of obesity. Annals of Medicine. 37(4):270-5. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16019725
Pandey, R., Mousawy, K., Nagarkatti, M., & Nagarkatti, P. (2009). Endocannabinoids and immune regulation. Pharmacological Research : The Official Journal of the Italian Pharmacological Society, 60(2), 85–92. http://doi.org/10.1016/j.phrs.2009.03.019
Ruehle, S., Rey, A. A., Remmers, F., & Lutz, B. (2012). The endocannabinoid system in anxiety, fear memory and habituation. Journal of Psychopharmacology (Oxford, England), 26(1), 23–39. http://doi.org/10.1177/0269881111408958
Smith, S. & Wagner, M. (2014) Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions. Neuro Endocrinol Letters. 35(3):198-201. http://www.ncbi.nlm.nih.gov/pubmed/24977967
This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.